Updates are available Correction dated 2026-06-19
Click to view Correction: https://doi.org/10.1007/s13187-026-02931-z
-
Authors
Blue, Brandon
Lake, Paige https://orcid.org/0000-0002-5591-6417
Pidala, Joseph
Jim, Heather
Locke, Frederick L.
Vadaparampil, Susan
- License Information
-
More Information
Article History
Received: 4 January 2026
Accepted: 3 May 2026
First Online: 30 May 2026
Change Date: 19 June 2026
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1007/s13187-026-02931-z
Declarations
:
: Dr. Blue has the following COIs to report: Consultant/Advisory Board: Bristol Meyers Squibb; Takeda. Speakers Bureau/Honoraria: Johnson & Johnson; Kite; Pfizer. Dr. Locke has the following COIs to report: Scientific Advisory Role/Consulting Fees: A2, Adaptive Biotechnologies, Allogene, Amgen, Astra-Zeneca, Bluebird Bio, BMS, Boxer Capital Management, Calibr, Caribou Biosciences, CytoArt (BioSwan Laboratories), EcoR1 Capital, Evoke Incisive Health Limited, Gerson Lehrman Group (GLG), Iovance, Kite Pharma, Janssen (J&J), Legend Biotech, Miltenyi, Novartis, Pagona Health, Pfizer, Poseida, Regeneron Clinical Sciences, SanaData Safety Monitoring Board: Data and Safety Monitoring Board for the National Cancer Institute (NCI), Safety Oversight CAR T-cell Therapies Committee.Research Contracts or Grants to my Institution for Service: 2SeventyBio (Institutional), Allogene (Institutional), BMS (Institutional), Incyte (Institutional), Kite Pharma (Institutional), Leukemia and Lymphoma Society Scholar in Clinical Research (PI: Locke), Mark Foundation, National Cancer Institute (NCI)Patents, Royalties, Other Intellectual Property: Several patents held by the institution in my name (unlicensed) in the field of cellular immunotherapy.Education or Editorial Activity: Aptitude Health, ASH, ASTCT, Clinical Care Options Oncology, Society for Immunotherapy of Cancer.
